Discovery of therapeutic deubiquitylase effector molecules: Current perspectives

Journal of Biomolecular Screening

Volumn 19, Issue 7, 2014, Pages 989-999

  Nicholson, B ^a   Kumar, Suresh ^a   Agarwal, S ^a   Eddins, M J ^a   Marblestone, J G ^a   Wu, J ^a   Kodrasov, M P ^a   Larocque, J P ^a   Sterner, D E ^a   Mattern, M R ^a  

^a Progenra Inc   (United States)

Author keywords

drug discovery; protease; review; screening assays; ubiquitin pathway

Indexed keywords

ADAPTOR PROTEIN; BORTEZOMIB; CARFILZOMIB; CLASPIN PROTEIN; CYSTEINE PROTEINASE; DEUBIQUITINASE; DEUBIQUITYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; POMALIDOMIDE; PROTEASOME INHIBITOR; PROTEIN MDM2; THALIDOMIDE DERIVATIVE; TRANSCRIPTION FACTOR FOXP3; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; USP14 PROTEIN; USP19 PROTEIN; USP46 PROTEIN; USP7 PROTEIN; LIGAND; PROTEASOME; THALIDOMIDE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

CARDIOVASCULAR DISEASE; CELL FUNCTION; DEGENERATIVE DISEASE; DNA DAMAGE; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN TARGETING; REVIEW; UBIQUITINATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG SCREENING; METABOLISM; NEOPLASMS; PROTEIN CONFORMATION;

ANIMALS; CATALYTIC DOMAIN; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; LIGANDS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN CONFORMATION; THALIDOMIDE; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84904600218     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114527312     Document Type: Review

References (80)

1. Hershko A., Ciechanover A.. The Ubiquitin-Proteasome Pathway. Annu. Rev. Biochem. 1998 ; 67: 425-479
2. Ciechanover A., Schwartz A. L.. The Ubiquitin-Proteasome Pathway: The Complexity and Myriad Functions of Proteins Death. Proc. Natl. Acad. Sci. USA. 1998 ; 95: 2727-2730
3. Ciechanover A.. The Ubiquitin Proteolytic System and Pathogenesis of Human Diseases: A Novel Platform for Mechanism-Based Drug Targeting. Biochem. Soc. Trans. 2003 ; 31: 474-481
4. Hochstrasser M.. Ubiquitin-Dependent Protein Degradation. Annu. Rev. Genet. 1996 ; 30: 405-439
5. Ciechanover A.. Proteolysis: From the Lysosome to Ubiquitin and the Proteasome. Nat. Rev. Mol. Cell Biol. 2005 ; 6: 79-87
6. Adams J., Kauffman M.. Development of the Proteasome Inhibitor Velcade (Bortezomib). Cancer Invest. 2004 ; 22: 304-311
7. Orlowski R. Z., Kuhn D. J.. Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade. Clin. Cancer Res. 2008 ; 14: 1649-1657
8. Suzuki E., Demo S., Deu E., et al. Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells. PLoS One. 2011 ; 6: e27996
9. Pellom S. T., Shanker A.. Development of Proteasome Inhibitors as Therapeutic Drugs. J. Clin. Cell. Immunol. 2012 ; S5: 5
10. Ciechanover A.. Ubiquitin-Mediated Degradation of Cellular Proteins: Why Destruction Is Essential for Construction, and How It Got from the Test Tube to the Patient's Bed. Isr. Med. Assoc. J. 2001 ; 3: 319-327
11. Hoeller D., Dikic I.. Targeting the Ubiquitin System in Cancer Therapy. Nature. 2009 ; 458: 438-444
12. Nicholson B., Marblestone J. G., Butt T. R., et al. Deubiquitinating Enzymes as Novel Anticancer Targets. Future Oncol. 2007 ; 3: 191-199
13. Shi D., Grossman S. R.. Ubiquitin Becomes Ubiquitous in Cancer: Emerging Roles of Ubiquitin Ligases and Deubiquitinases in Tumorigenesis and as Therapeutic Targets. Cancer Biol. Ther. 2010 ; 10: 737-747
14. Reyes-Turcu F. E., Ventii K. H., Wilkinson K. D.. Regulation and Cellular Roles of Ubiquitin-Specific Deubiquitinating Enzymes. Annu. Rev. Biochem. 2009 ; 78: 363-397
15. Clague M. J., Coulson J. M., Urbe S.. Cellular Functions of the DUBs. J. Cell Sci. 2012 ; 125: 277-286
16. Huang F., Zeng X., Kim W., et al. Lysine 63-Linked Polyubiquitination Is Required for EGF Receptor Degradation. Proc. Natl. Acad. Sci. USA. 2013 ; 110: 15722-15727
17. Urbe S.. Ubiquitin and Endocytic Protein Sorting. Essays Biochem. 2005 ; 41: 81-98
18. Ciechanover A., Orian A., Schwartz A. L.. The Ubiquitin-Mediated Proteolytic Pathway: Mode of Action and Clinical Implications. J. Cell Biochem. 2000 ; 77: 40-51
19. Lee M. J., Lee B. H., Hanna J., et al. Trimming of Ubiquitin Chains by Proteasome-Associated Deubiquitinating Enzymes 2011. Mol. Cell. Proteom 10. 110: 003871
20. Komander D., Clague M. J., Urbe S.. Breaking the Chains: Structure and Function of the Deubiquitinases. Nat. Rev. Mol. Cell Biol. 2009 ; 10: 550-563
21. Weathington N. M., Sznajder J. I., Mallampalli R. K.. The Emerging Role of the Ubiquitin Proteasome in Pulmonary Biology and Disease. Am. J. Respir. Crit. Care Med. 2013 ; 188: 530-537
22. Ying Z., Wang H., Wang G.. The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases. Curr. Pharm. Des. 2013 ; 19: 3305-3314
23. Everett R. D., Meredith M., Orr A., et al. A Novel Ubiquitin-Specific Protease Is Dynamically Associated with the PML Nuclear Domain and Binds to a Herpesvirus Regulatory Protein. Embo. J. 1997 ; 16: 1519-1530
24. Nicholson B., Suresh Kumar K. G.. The Multifaceted Roles of USP7: New Therapeutic Opportunities. Cell. Biochem. Biophys. 2011 ; 60: 61-68
25. Li M., Brooks C. L., Kon N., et al. A Dynamic Role of HAUSP in the p53-Mdm2 Pathway. Mol. Cell. 2004 ; 13: 879-886
26. Colland F., Formstecher E., Jacq X., et al. Small-Molecule Inhibitor of USP7/HAUSP Ubiquitin Protease Stabilizes and Activates p53 in Cells. Mol. Cancer Ther. 2009 ; 8: 2286-2295
27. Wrigley J. D., Eckersley K., Hardern I. M., et al. Enzymatic Characterisation of USP7 Deubiquitinating Activity and Inhibition. Cell. Biochem. Biophys. 2011 ; 60: 99-111
28. Weinstock J., Wu J., Cao P., et al. Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. ACS Med. Chem. Lett. 2012 ; 3: 789-792
29. Faustrup H., Bekker-Jensen S., Bartek J., et al. USP7 Counteracts SCFbetaTrCP- but Not APCCdh1-Mediated Proteolysis of Claspin. J. Cell Biol. 2009 ; 184: 13-19
30. Fontenot J. D., Gavin M. A., Rudensky A. Y.. Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells. Nat. Immunol. 2003 ; 4: 330-336
31. van Loosdregt J., Fleskens V., Fu J., et al. Stabilization of the Transcription Factor Foxp3 by the Deubiquitinase USP7 Increases Treg-Cell-Suppressive Capacity. Immunity. 2013 ; 39: 259-271
32. Colleran A., Collins P. E., O'Carroll C., et al. Deubiquitination of NF-kappaB by Ubiquitin-Specific Protease-7 Promotes Transcription. Proc. Natl. Acad. Sci. USA. 2013 ; 110: 618-623
33. Wilson S. M., Bhattacharyya B., Rachel R. A., et al. Synaptic Defects in Ataxia Mice Result from a Mutation in Usp14, Encoding a Ubiquitin-Specific Protease. Nat. Genet. 2002 ; 32: 420-425
34. Koulich E., Li X., DeMartino G. N.. Relative Structural and Functional Roles of Multiple Deubiquitylating Proteins Associated with Mammalian 26S Proteasome. Mol. Biol. Cell. 2008 ; 19: 1072-1082
35. Lee B. H., Lee M. J., Park S., et al. Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of USP14. Nature. 2010 ; 467: 179-184
36. Lappe-Siefke C., Loebrich S., Hevers W., et al. The Ataxia (axJ) Mutation Causes Abnormal GABAA Receptor Turnover in Mice. PLoS Genet. 2009 ; 5: e1000631
37. Kowalski J. R., Dahlberg C. L., Juo P.. The Deubiquitinating Enzyme USP-46 Negatively Regulates the Degradation of Glutamate Receptors to Control Their Abundance in the Ventral Nerve Cord of Caenorhabditis elegans. J. Neurosci. 2011 ; 31: 1341-1354
38. Kowalski J. R., Juo P.. The Role of Deubiquitinating Enzymes in Synaptic Function and Nervous System Diseases. Neural Plast. 2012 ; 2012: 892749
39. Wing S. S.. Deubiquitinases in Skeletal Muscle Atrophy. Int. J. Biochem. Cell Biol. 2013 ; 45: 2130-2135
40. Sundaram P., Pang Z., Miao M., et al. USP19-Deubiquitinating Enzyme Regulates Levels of Major Myofibrillar Proteins in L6 Muscle Cells. Am. J. Physiol. Endocrinol. Metab. 2009 ; 297: E1283 - E1290
41. Roubenoff R., Heymsfield S. B., Kehayias J. J., et al. Standardization of Nomenclature of Body Composition in Weight Loss. Am. J. Clin. Nutr. 1997 ; 66: 192-196
42. Wilkinson K. D., Hochstrasser M. Ubiquitin and the Biology of the Cell. Peters H. Finley D., ed. Plenum Press: New York ; 1998: 99-125.
43. Amerik A. Y., Hochstrasser M.. Mechanism and Function of Deubiquitinating Enzymes. Biochim. Biophys. Acta. 2004 ; 1695: 189-207
44. Reyes-Turcu F. E., Wilkinson K. D.. Polyubiquitin Binding and Disassembly by Deubiquitinating Enzymes. Chem. Rev. 2009 ; 109: 1495-1508
45. Chen J., Dexheimer T. S., Ai Y., et al. Selective and Cell-Active Inhibitors of the USP1/UAF1 Deubiquitinase Complex Reverse Cisplatin Resistance in Non-Small Cell Lung Cancer Cells. Chem. Biol. 2011 ; 18: 1390-1400
46. Colombo M., Vallese S., Peretto I., et al. Synthesis and Biological Evaluation of 9-Oxo-9H-Indeno[1,2-b]Pyrazine-2,3-Dicarbonitrile Analogues as Potential Inhibitors of Deubiquitinating Enzymes. Chem. Med. Chem. 2010 ; 5: 552-558
47. Reverdy C., Conrath S., Lopez R., et al. Discovery of Specific Inhibitors of Human USP7/HAUSP Deubiquitinating Enzyme. Chem. Biol. 2012 ; 19: 467-477
48. Byun S., Lee S. Y., Lee J., et al. USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer. Clin. Cancer Res. 2013 ; 19: 3894-3904
49. Altun M., Kramer H. B., Willems L. I., et al. Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes. Chem. Biol. 2011 ; 18: 1401-1412
50. Chauhan D., Tian Z., Nicholson B., et al. A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance. Cancer Cell. 2012 ; 22: 345-358
51. Murai J., Yang K., Dejsuphong D., et al. The USP1/UAF1 Complex Promotes Double-Strand Break Repair through Homologous Recombination. Mol. Cell. Biol. 2011 ; 31: 2462-2469
52. D'Arcy P., Brnjic S., Olofsson M. H., et al. Inhibition of Proteasome Deubiquitinating Activity as a New Cancer Therapy. Nat. Med. 2011 ; 17: 1636-1640
53. Dang L. C., Melandri F. D., Stein R. L.. Kinetic and Mechanistic Studies on the Hydrolysis of Ubiquitin C-Terminal 7-Amido-4-Methylcoumarin by Deubiquitinating Enzymes. Biochemistry. 1998 ; 37: 1868-1879
54. Layfield R., Franklin K., Landon M., et al. Chemically Synthesized Ubiquitin Extension Proteins Detect Distinct Catalytic Capacities of Deubiquitinating Enzymes. Anal. Biochem. 1999 ; 274: 40-49
55. Tirat A., Schilb A., Riou V., et al. Synthesis and Characterization of Fluorescent Ubiquitin Derivatives as Highly Sensitive Substrates for the Deubiquitinating Enzymes UCH-L3 and USP-2. Anal. Biochem. 2005 ; 343: 244-255
56. Nicholson B., Leach C. A., Goldenberg S. J., et al. Characterization of Ubiquitin and Ubiquitin-Like-Protein Isopeptidase Activities. Protein Sci. 2008 ; 17: 1035-1043
57. Tian X., Isamiddinova N. S., Peroutka R. J., et al. Characterization of Selective Ubiquitin and Ubiquitin-Like Protease Inhibitors Using a Fluorescence-Based Multiplex Assay Format. Assay Drug Dev. Technol. 2011 ; 9: 165-173
58. Orcutt S. J., Wu J., Eddins M. J., et al. Bioluminescence Assay Platform for Selective and Sensitive Detection of Ub/Ubl Proteases. Biochim. Biophys. Acta. 2012 ; 1823: 2079-2086
59. Mevissen T. E., Hospenthal M. K., Geurink P. P., et al. OTU Deubiquitinases Reveal Mechanisms of Linkage Specificity and Enable Ubiquitin Chain Restriction Analysis. Cell. 2013 ; 154: 169-184
60. Parker G. J., Law T. L., Lenoch F. J., et al. Development of High Throughput Screening Assays Using Fluorescence Polarization: Nuclear Receptor-Ligand-Binding and Kinase/Phosphatase Assays. J. Biomol. Screen. 2000 ; 5: 77-88
61. Boisclair M. D., McClure C., Josiah S., et al. Development of a Ubiquitin Transfer Assay for High Throughput Screening by Fluorescence Resonance Energy Transfer. J. Biomol. Screen. 2000 ; 5: 319-328
62. Hong C. A., Swearingen E., Mallari R., et al. Development of a High-Throughput Time-Resolved Fluorescence Resonance Energy Transfer Assay for TRAF6 Ubiquitin Polymerization. Assay Drug Dev. Technol. 2003 ; 1: 175-180
63. Geurink P. P., El Oualid F., Jonker A., et al. A General Chemical Ligation Approach towards Isopeptide-Linked Ubiquitin and Ubiquitin-Like Assay Reagents. Chembiochem. 2012 ; 13: 293-297
64. Harris D. C. Quantitative Chemical Analysis. 8 th ed.; FreemanW. H.: New York, 2010; pp. 419-444. Freeman W. H., ed. New York ; 2010: 419-444.
65. Zheng J.. Spectroscopy-Based Quantitative Fluorescence Resonance Energy Transfer Analysis. Meth. Mol. Biol. 2006 ; 337: 65-77
66. Keusekotten K., Elliott P. R., Glockner L., et al. OTULIN Antagonizes LUBAC Signaling by Specifically Hydrolyzing Met1-Linked Polyubiquitin. Cell. 2013 ; 153: 1312-1326
67. Ye Y., Blaser G., Horrocks M. H., et al. Ubiquitin Chain Conformation Regulates Recognition and Activity of Interacting Proteins. Nature. 2012 ; 492: 266-270
68. Virdee S., Ye Y., Nguyen D. P., et al. Engineered Diubiquitin Synthesis Reveals Lys29-Isopeptide Specificity of an OTU Deubiquitinase. Nat. Chem. Biol. 2010 ; 6: 750-757
69. Arnst J. L., Davies C. W., Raja S. M., et al. High-Throughput Compatible Fluorescence Resonance Energy Transfer-Based Assay to Identify Small Molecule Inhibitors of AMSH Deubiquitinase Activity. Anal. Biochem. 2013 ; 440: 71-77
70. Fernandez-Montalvan A., Bouwmeester T., Joberty G., et al. Biochemical Characterization of USP7 Reveals Post-Translational Modification Sites and Structural Requirements for Substrate Processing and Subcellular Localization. FEBS J. 2007 ; 274: 4256-4270
71. Faesen A. C., Dirac A. M., Shanmugham A., et al. Mechanism of USP7/HAUSP Activation by Its C-Terminal Ubiquitin-Like Domain and Allosteric Regulation by GMP-Synthetase. Mol. Cell. 2011 ; 44: 147-159
72. Zhang Y., Zhou L., Rouge L., et al. Conformational Stabilization of Ubiquitin Yields Potent and Selective Inhibitors of USP7. Nat. Chem. Biol. 2013 ; 9: 51-58
73. Ernst A., Avvakumov G., Tong J., et al. A Strategy for Modulation of Enzymes in the Ubiquitin System. Science. 2013 ; 339: 590-595
74. Hagel M., Niu D., St Martin T., et al. Selective Irreversible Inhibition of a Protease by Targeting a Noncatalytic Cysteine. Nat. Chem. Biol. 2011 ; 7: 22-24
75. Salemme F. R.. High-Throughput Biochemistry Heats Up. Nat. Biotechnol. 2004 ; 22: 1100-1101
76. Grasberger B. L., Lu T., Schubert C., et al. Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells. J. Med. Chem. 2005 ; 48: 909-912
77. Pantoliano M. W., Petrella E. C., Kwasnoski J. D., et al. High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery. J. Biomol. Screen. 2001 ; 6: 429-440
78. Regnstrom K., Yan J., Nguyen L., et al. Label Free Fragment Screening Using Surface Plasmon Resonance as a Tool for Fragment Finding: Analyzing Parkin, a Difficult CNS Target. PLoS One. 2013 ; 8: e66879
79. Razinkov V. I., Treuheit M. J., Becker G. W.. Methods of High Throughput Biophysical Characterization in Biopharmaceutical Development. Curr. Drug Discov. Technol. 2013 ; 10: 59-70
80. Hu M., Li P., Li M., et al. Crystal Structure of a UBP-Family Deubiquitinating Enzyme in Isolation and in Complex with Ubiquitin Aldehyde. Cell. 2002 ; 111: 1041-1054